The Safety of Dapoxetine/Tadalafil Combination Therapy

Overview

This trial is active, not recruiting.

Conditions premature ejaculation, erectile dysfunction, safety issues
Treatment dapoxetine/tadalafil 30/20 mg film coated tablet
Phase phase 4
Sponsor Neutec Ar-Ge San ve Tic A.Ş
Start date September 2017
End date January 2020
Trial size 40 participants
Trial identifier NCT03177746, NEU-10.16

Summary

The purpose of this study is to evaluate the safety and efficacy of Dapoxetine/Tadalafil 30/20 mg film-coated tablet in the treatment of men with premature ejaculation and erectile dysfunction.

United States No locations recruiting
Other countries Turkey

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking none (open label)
Arm
dapoxetine/tadalafil 30/20 mg film coated tablet Tada Plus During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse. Study drug should not be used more than 1 tablet every 24 hours during the treatment.

Primary Outcomes

Secondary Outcomes

Eligibility Criteria

Male participants from 18 years up to 64 years old.

Inclusion Criteria: – 18-64 years old men, – Participants must be heterosexual males and in a stable monogamous sexual relationship with a female partner for at least 6 months and will continue throughout the study, – Clinical diagnosis of erectile dysfunction, IIEF score ≤21, – Premature Ejaculation Diagnostic Tool (PEDT) score must be ≥11 – Patients with life-long PE and acquired PE according to the description of International Society for Sexual Medicine (ISSM) , – The patient and his partner must have sexual intercourse twice a week for the duration of the study, – Commitment to comply with the study protocol, – Patients who sign informed consent form (ICF). Exclusion Criteria: – History of medical events such as surgical interventions or neurologic conditions (e.g., multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE, – Having genital abnormalities, except penile curvature unless not prevent sexual intercourse, – Developed erectile dysfunction or premature ejaculation due to drug use or quit taking drugs, – Any conditions that prevent sexual intercourse with partners – History of epilepsy, – Severe renal insufficiency, – Liver disease, – History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New York Cardiovascular Associates (NYCA) phase II-IV), atrioventricular block or message disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angina, life-threatening arrhythmia or hypotension, – Non-Arteritic Anterior ischemic optic neuropathy, – Patients who are not eligible to have sexual intercourse due to existing health problems, – Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer, abnormalities in ECG, severe systemic disease that cannot be controlled, – Systolic/Diastolic blood pressure at rest

Additional Information

Official title The Safety of Dapoxetine/Tadalafil Combination Therapy in Treatment of Men With Premature Ejaculation and Erectile Dysfunction

Call for more information

Phone
Email
Principal Investigator
Trial
Trial ID
Institution
Location

Request more information

Trial Details

  • home
  • trials
  • NCT03177746
  • Links
  • Conversations
  • Communities
  • Clinical trials
  • Partners
  • Resources
  • Tutorial
  • Glossary
  • Brochures
  • Web assets
  • Company
  • About
  • Terms
  • Privacy
  • Contact us
  • FAQ
  • Social
  • Stories
  • Quotes
  • Twitter
  • Facebook

Join the conversation

Request an invitation to join Smart Patients.